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CC BY-NC-ND license (http://creativeAbstract Cerebral ischemia may cause permanent brain damage and behavioral dysfunction.
The efficacy and mechanisms of pharmacological treatments administered immediately after
cerebral damage are not fully known. Sugammadex is a licensed medication. As other cyclodex-
trins have not passed the necessary phase tests, trade preparations are not available, whereas
sugammadex is frequently used in clinical anesthetic practice. Previous studies have not clearly
described the effects of the cyclodextrin family on cerebral ischemia/reperfusion (I/R) damage.
The aim of this study was to determine whether sugammadex had a neuroprotective effect
against transient global cerebral ischemia. Animals were assigned to control, sham-operated,
S 16 and S 100 groups. Transient global cerebral ischemia was induced by 10-minute occlusion
of the bilateral common carotid artery, followed by 24-hour reperfusion. At the end of the
experiment, neurological behavior scoring was performed on the rats, followed by evaluation
of histomorphological and biochemical measurements. Sugammadex 16 mg/kg and 100 mg/kg
improved neurological outcome, which was associated with reductions in both histological
and neurological scores. The hippocampus TUNEL (terminal deoxynucleotidyl transferase dUTP
nick end labeling) and caspase results in the S 16 and S 100 treatment groups were significantly
lower than those of the I/R group. Neurological scores in the treated groups were significantly
higher than those of the I/R group. The study showed that treatment with 16 mg/kg and 100 mg/
kg sugammadex had a neuroprotective effect in a transient global cerebral I/R rat model. How-
ever, 100 mg/kg sugammadex was more neuroprotective in rats.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).eclare no conflicts of interest.
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Reperfusion after cerebral ischemia may cause secondary
neurological dysfunction and neuronal death by multiple
pathophysiological mechanisms during a variety of surgical
procedures such as cardiopulmonary bypass and carotid and
cerebral aneurysm [1]. Specifically during general anes-
thesia, the most frequently used inhalation agents and
intravenous anesthetic medications are neuroprotective
against cerebral ischemia/reperfusion (I/R) injury, and
their roles in neuroprotection have been shown [2]. For
many years protecting the patient’s brain during the
operation has been the most important factor for anes-
thetists [3,4]. To achieve this goal, selection of the most
appropriate agents during the perioperative period and
research to achieve this aim have been performed [2].
Sugammadex is a modified g-cyclodextrin molecule that
has recently begun to be used in clinical neuromuscular
pharmacology. Sugammadex, which already plays an
important role in anesthetic administration despite its
novelty, is an agent with controversial effects on cerebral
I/R injury. The neuroprotective effects of cyclodextrins
have been shown previously [5,6]. In addition, no study
assessing the neuroprotective effect of sugammadex in an
in vivo cerebral I/R injury model has been conducted.
Although a variety of experimental studies have shown the
neuroprotective characteristics of other cyclodextrins, the
adverse effect of sugammadex on neuronal cell cultures has
led to debate on this topic [7]. Their molecular pathogenic
mechanisms are not clear. However, studies on this topic
have led to a variety of results indicating that the mecha-
nisms are at both the receptor and neuronal membrane
level.
The hypothesis of this study is that, similar to other
cyclodextrins, a g-cyclodextrin will reduce cerebral I/R
injury in a global cerebral hypoxia model in rats and may
have neuroprotective effects. In the current study, we
aimed to test this hypothesis using a temporary global ce-
rebral I/R model induced by bilateral common carotid
occlusion.
Methods
After obtaining permission from the Dokuz Eylul University
School of Medicine (DEUSM) Local Animal Experiments
Ethical Committee, Izmir, Turkey (05.09.2015, Number: 15/
2015, Yılmaz O), the study was carried out at the DEUSM
Animal Experiment Laboratories, Izmir, Turkey. The study
included 28 Wistar Albino rats that weighed between 250 g
and 300 g. The rats were housed in temperature-controlled
(22e24C) rooms that were lit on a daily schedule
(12:12 hours light/dark) before the study. All of the rats
were fed standard rat pellets. During the experimental
period, the care of the laboratory animals was conducted in
accordance with international guidelines.
Experimental design
Male rats were fasted for 12 hours before operation. The
weights and ages of all of the rats were recorded. The rats
were randomly divided into four groups of seven rats: Shamgroup, I/R group, I/R þ S 16 group, and I/R þ S 100 group.
Using sterile techniques, all of the rats had a 24 G (Vasofix
Safety FEP, Braun, Germany) cannula placed in the lateral
tail vein for the administration of 5% dextrose (1 mL total
volume) and medications during the study.
Bilateral common carotid artery occlusion
The experimental model was based on a previously re-
ported model, with several modifications [8,9]. The animals
were anesthetized with 80 mg/kg ketamine hydrochloride
and 12 mg/kg xylazine administered intraperitoneally.
After the rats were anesthetized, the bilateral common
carotid arteries were exposed and carefully separated from
the carotid sheath and the cervical sympathetic and vagal
nerves through a ventral cervical incision. The bilateral
common carotid arteries were occluded with nontraumatic
aneurysm clips in ischemic rats but were not clamped in
sham-operated rats. Complete interruption of the blood
flow was confirmed by observing the central artery in the
retina with an ophthalmoscope. The body temperature of
the rats was maintained at 37.0  0.5C during this pro-
cedure. In this model, 10 minutes of ischemia and 24 hours
of reperfusion were induced. After the ischemic period, the
rats were treated with sugammadex 16 mg/kg (S 16 group)
and sugammadex 100 mg/kg (S 100 group) (intravenous and
total volume 1 mL) in the 5th minute of reperfusion.
Sugammadex was diluted with normal saline (0.9% NaCl).
The same surgical procedure was performed in the I/R
group, but the rats were not treated with sugammadex.
The neck incision was closed with sutures (3.0 silk), and the
animals were allowed to awaken. After 24 hours, the
neurological condition of the rats was assessed with a
scoring system [9,10]. The sugammadex doses were deter-
mined according to doses used in previous experimental
studies [11e14].
Assessment of neurological behavior
After the 24-hour reperfusion period, behavior was
assessed before sacrifice. The neurological examination
assessed rats with a six-stage test scoring system as
described by Garcia et al. [9] and with a beam-walking test
[10].
Neurological scoring system of Garcia et al.
1, spontaneous activity; 2, symmetrical movement in four
extremities; 3, forepaw outstretching; 4, limb placement
test, 5, climbing; 6, body proprioception; and 7, response
to contact with whiskers. At the end of the assessment, the
points given to the rat for each of the six tests were added
together. The lowest neurological score was 3 and the
highest was 18.
Beam-walking test
0, rat falls; 1, rat does not traverse the beam, but continues
to sit on the beam; 2, rat begins to walk and falls (rat falls
when walking); 3, rat traverses the beam but this is not
accompanied by movement of the affected hindlimb; 4, rat
traverses the beam but expends > 50% greater effort (rat
traverses with> 50% footslips); 5, rat traverses the beam
and shows less excess effort (rat has few footslips); and 6,
rat traverses the beam without footslips. In all groups of
rats with completed neurological assessment, anesthesia
294 S. Ozbilgin et al.was administered, and the brains were rapidly removed for
histological examination of brain tissue slices. For
biochemical testing, blood was taken by cardiac puncture
and, at the same time, this method was used to end the
study by sacrificing the rats by exsanguination.Histomorphological evaluation
The brain tissues were fixed in 10% formalin solution, pro-
cessed by routine histological methods, and embedded in
paraffin blocks. Blocks were sectioned coronally into
sequential 5-mm sections. Each sample was subjected to
estimation of neuron number by taking three consecutive
coronal sections through the hippocampus [CA1, CA2, CA3,
and gyrus dentatus (GD) regions] and parietal cortex that
corresponded approximately to Plates 22 and 23, respec-
tively, in the rat atlas of Paxinos and Watson [15]. All sec-
tions were stained with cresyl violet for stereological and
histomorphological evaluations [16].
Estimation of neuron density in hippocampus and
parietal cortex
The images were analyzed using a computer-assisted image
analyzer system consisting of a microscope (Olympus BX-51;
Olympus, Tokyo, Japan) equipped with a high-resolution
video camera (Olympus DP-71). The number of neurons in
CA1, CA2, CA3, and GD of the hippocampus and parietal
cortex regions were counted with the help of a counting
frame of 15,800 mm2 viewed through a 20 lens (Olympus
U) on the monitor. The counting frame was randomly placed
three times on the image analyzer system monitor. The
number of neurons was counted (UTHSCA Image Tool for
Windows, version 3.0, Comprehensive Dentistry, Twain),
and the average was taken. Hippocampal, prefrontal, and
parietal cortex neuron densities were calculated [16].
In situ cell death detection
To detect DNA fragmentation in cell nuclei, the TUNEL
(terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling) reaction was applied to paraffin sections.
The DeadEnd Colorimetric TUNEL system kit (In Situ Cell
Death Detection Kit; Roche Diagnostics, Mannheim, Ger-
many) was used for detection of apoptotic cells. Serial 5-
mm thick paraffin-embedded sections were deparaffinized,
rehydrated in graded alcohol, and pretreated in proteinase
K (20 mg/mL) for 15 minutes at 37C. After washing in
phosphate-buffered saline (PBS), specimens were incu-
bated with fluorescein-labeled dUTP and TdT at 37C for
1 hour. Then, converter peroxidase (POD) solution was
applied to the slides at 37C for 30 minutes. Sections were
stained with diaminobenzidine (Roche Diagnostics), coun-
terstained with Mayer’s hematoxylin, and analyzed using a
light microscope [16].
Immunohistochemistry was also performed for active
caspase-3 (AB3623; Millipore, Temecula, CA, USA, and
polyclonal antibody). After deparaffinization and rehydra-
tion, the sections were treated with 10mM citrate buffer
(Cat No. AP-9003-125 Labvision, Fremont, CA, USA; pH 6) in
a microwave oven for 5 minutes. The sections were washed
with PBS and incubated in a solution of 3% H2O2 for 5 mi-
nutes at room temperature to inhibit endogenousperoxidase activity. After washing with PBS, the sections
were incubated with normal serum blocking solution at
37C for 30 minutes. The sections were again incubated in a
humid chamber for 18 hours at 4C with antibody active
caspase-3 (1/100); thereafter, the sections were incubated
with biotinylated immunoglobulin G and then with strep-
tavidin conjugated to horseradish peroxidase at 37C for
30 minutes (Invitrogen-Plus Broad Spectrum 85-9043; Invi-
trogen, Carlsbad, CA, USA). The sections were finally
stained with diaminobenzidine (Roche Diagnostics), coun-
terstained with Mayer’s hematoxylin, and analyzed using a
light microscope [16]. For the quantitative measurement of
the number of cells that underwent apoptosis, 1000 cells
were randomly counted including cells showing apoptotic
morphology in the hippocampus and parietal cortex, and
apoptotic cell percentages were calculated [16].Measurement of antioxidant enzyme activity and
malondialdehyde content
For all groups, intracardiac blood was analyzed by the
DEUSM Biochemistry Department Central Laboratory using
the following tests.
Total antioxidant status measurement
Total antioxidant status (TAS) was studied using the Rel
Assay trade kit (Cat No. RL0017, Gaziantep, Turkey). The
principle of the method is based on transformation of
dark greeneblue-colored 3-ethylbenzothiazoline-6-sul-
phonic acid (ABTS) radicals to the colorless form of ABTS in
the presence of antioxidants. The ABTS product becomes
colorless in proportion to the amount of antioxidant pre-
sent. The Trolox used for calibration is a vitamin E analog.
The results are given as Trolox equivalents. The method
was carried out in a Beckman Olympus AU 5800 device
(California, USA) with autoanalysis using spectrophoto-
metric methods. The measurement interval was 0e2.75
Trolox equivalent/L. The managed measurement interval
was 0e2.75 Trolox equivalent/L [17].
Superoxide dismutase activity measurement
Superoxide dismutase (SOD) activity was measured using a
trade reactive kit (RANSOD, catalogue No. SD125, Randox
Laboratories, Crumlin, County Antrim, BT29 4QY, UK)
based on spectrophotometric measurement at 505 nm of
red formazan stain formed by a chemical reaction be-
tween oxygen radicals, formed by xanthine and xanthine
oxidase, with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-
phenyltetrazolium chloride (INT). The procedure was
carried out by setting a Beckman Olympus AU 5800 device
for spectrophotometric autoanalysis. The measurement
interval of the method was 0.06e4.52 U/mL [17].
Glutathione peroxidase activity measurement
Glutathione peroxidase (GPx) was studied using a BioVision
trade kit (Catalogue No. K762-100; BioVision Corporation,
Milpitas, CA, USA). The procedure was carried out by
setting a Beckman Olympus AU 5800 device for spectro-
photometric autoanalysis. The principle of the method is
based on the reduction of cumene hydroperoxide by GPx. In
this process, glutathione (GSH) was oxidized to glutathione
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used. As a result, there was a direct correlation with the
decrease in NADPH, depending on how much GPx was pre-
sent in the sample. This decrease was spectrophotometri-
cally monitored at 340 nm. The minimum detection limit
was 0.5 mU/mL [17].
Malondialdehyde content measurement
Malondialdehyde (MDA) was measured using a trade reac-
tive kit (Lipid Peroxidation Colorimetric Assay Kit, Cata-
logue No. K739-100; BioVision Corporation) based on
spectrophotometric measurement at 532 nm of pink color
formed by reaction with thiobarbituric acid. The mea-
surement interval was 0.1e20.0 nmol/L [17].
Statistical analysis
For statistical analysis, we used SPSS version 15.0 (SPSS
Inc., Chicago, IL, USA). To evaluate the significance of the
comparisons between groups, ManneWhitney U test and c2
tests were used. A p value < 0.05 was considered statisti-
cally significant.Results
The Sham group included six rats because one of the rats
died during the experimental surgery procedures.
Neurological scores
The evaluation of neurological scores among the groups
revealed that, in the Sham group, body proprioception,
response to vibrissae touch, and total neurological score
were significantly higher than in the I/R group (p < 0.001).
In the S 16 and S 100 groups, body proprioception, response
to vibrissae touch, and total neurological scores were
significantly higher than in the I/R group (p < 0.05; Table
1).
The total neurological score obtained by adding the total
neurological score to the beam-walking score was found to
be significantly higher in the Sham group than in the I/R
group (p < 0.001). These values were also found to be
significantly higher in the S 16 and S 100 treatment groups
than in the I/R group (p < 0.05; Table 2).
Histological assessment
Histological evaluation assessed the hippocampus (CA1,
CA2, CA3, and GD regions) and parietal cortex regions in all
rats included in the study in terms of neuron counts and
immunohistochemistry (TUNEL and caspase; Figures 1 and
2). In the Sham group, the total neuron counts in the hip-
pocampus CA1, CA2, CA3, and GD regions were significantly
higher than those in the I/R group (p < 0.05; Figures 1 and
2). This result indicates that the I/R model was successfully
induced in the rats. The total neuron counts in the hippo-
campus CA1, CA2, CA3, and GD regions in the S 16 and S 100
treatment groups were significantly higher than those in the
I/R group (p < 0.05; Table 3).Evaluation of the immunohistochemistry scores from
both the TUNEL and caspase assays in the hippocampus of
the Sham group revealed that they were significantly lower
than those in the I/R group (p < 0.05). The results obtained
from the parietal cortex were similar. The hippocampus
TUNEL and caspase results in the S 16 and S 100 treatment
groups were significantly lower than those in the I/R group
(p < 0.05; Table 4).
Biochemical measurements
Six blood samples were taken; therefore, there was a lack
of serum from the groups. All measurements of antioxidant
enzyme activity (TAS, GPx, and SOD) and MDA content in
the Sham group were significantly different from those in
the I/R group (p < 0.05). The TAS, GPx, SOD, and MDA
values in the Sham group were not significantly different
from those in the S 16 and S 100 groups (p > 0.05). The TAS,
GPx, SOD, and MDA values in the I/R group were not
significantly different from those in the S 16 and S 100
groups (p > 0.05; Table 5).
Discussion
This study evaluated the neuronal effects of sugammadex
in a transient global cerebral ischemia model in rats. Ex-
amination of the histological findings and neurological
behavior scores showed that doses of 16 mg/kg and 100 mg/
kg sugammadex reduced cerebral I/R damage.
The evaluation of the functional outcome, in addition to
histological changes, is increasingly acknowledged in the
experimental cerebral I/R model because improvement of
the functional outcome is a primary goal of cere-
broprotective therapies. Previous studies aiming to reduce
I/R injury have been conducted using a variety of medica-
tions and treatment models.
Zhou et al. [18] showed that mild and moderate hyper-
capnia had neuroprotective effects in rats with cerebral I/R
injury. Kakkar et al. [19] reported the protective role of
curcumin against cerebral ischemic insult, provided that it
is suitably packaged for improved brain delivery. Other
researchers [20] have shown the neuroprotective effect of
dauricine after cerebral I/R injury. They suggested that the
mechanism of the neuroprotective effect of dauricine after
cerebral I/R injury may partly be related to inhibition of
neuronal cell apoptosis in the penumbra. There is a study
evaluating the effects of cerebral I/R at the receptor level.
Discoidin domain receptor 1 has been shown to mediate
matrix metalloproteinase-9 secretion and to degrade all
extracellular matrix compounds in mammalian tumor cells.
Discoidin domain receptor 1 may represent a molecular
target for the prevention of bloodebrain barrier (BBB)
disruption after cerebral I/R injury [21]. Reactive oxygen
species play a significant role in neuron loss after cerebral
ischemic injury. Carnosine and punicalagin have both
antioxidant and neuroprotective effects against reactive
oxygen species [22,23]. Currently, there is a trend in which
researchers investigate the neuroprotective effects of the
most commonly used agents in clinical and surgical prac-
tice. Lithium and lamotrigine, which are used to treat mood
disorders, are among these. Ozkul et al. [24] found that
Table 1 Evaluation of neurological scoring system in groups.
Spontaneous
Activity
Symmetry
in the
movement of
4 limbs
Forepaw
outstretching
Limp
placement
test
Climbing Body
proprioception
Response
to vibrissae
touch
Total
neurological
score
Sham group
(n Z 6)
3.0  0.0 3.0  0.0 3.0  0.0 2.0  0.0 3.0  0.0 3.0  0.0b 3.0  0.00b 20.0  0.00b,c
I/R group
(n Z 7)
2.50  0.83 2.66  0.51 2.33  0.51 1.33  0.51 2.16  0.98 1.0  0.0a,c,d 1.0  0.0a,c,d 13.0  2.0a,b,d
S 16 group
(n Z 7)
3.0  0.0 2.71  0.48 2.85  0.37 1.42  0.53 2.85  0.37 2.85  0.37b 2.85  0.37b 18.57  1.71a,b
S 100 group
(n Z 7)
3.0  0.0 3.0  0.0 3.0  0.0 2.0  0.0 3.0  0.0 2.85  0.37b 2.85  0.37b 19.71  0.75b
Data are presented as mean  standard deviation.
I/R Z ischemiaereperfusion.
a p < 0.05, compared with Sham group, ManneWhitney U test.
b p < 0.05, compared with I/R group, ManneWhitney U test.
c p < 0.05, compared with S 16 group, ManneWhitney U test.
d p < 0.05, compared with S 100 group, ManneWhitney U test.
Table 2 Total neurological score and beam-walking score.
Total neurological score Beam walking Total neurological score
Sham group (n Z 6) 20.0  0.0b,c 6.0  0.0b 26.0  0.0b,c
I/R group (n Z 7) 13.0  2.0a,c,d 3.33  0.51a,c,d 16.33  2.50a,c,d
S16 group (n Z 7) 18.57  1.71a,b 5.28  0.75b 23.85  2.26a,b
S 100 group (n Z 7) 19.71  0.75b 5.71  0.75b 25.42  0.97b
Data are presented as mean  standard deviation.
I/R Z ischemiaereperfusion.
a p < 0.05, compared with Sham group, ManneWhitney U test.
b p < 0.05, compared with I/R group, ManneWhitney U test.
c p < 0.05, compared with S 16 group, ManneWhitney U test.
d p < 0.05, compared with S 100 group, ManneWhitney U test.
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learning memory deficits in global cerebral ischemia
without any significant effect of dosage in a global cerebral
ischemia rat model. Their findings suggest that lithium and
lamotrigine decrease spatial learning memory deficits,
accompanied by lower oxidative nitrosative stress in global
cerebral ischemia [24].
In previous studies, although there have been many
experimental agents evaluated for neuroprotective effects
in the global cerebral I/R models, many are not accessible,
not easy to use, or not licensed for use in routine clinical
practice. The neuroprotective and neurotoxic effects of
both volatile inhalation and intravenous agents used for
anesthesia during surgical operations have been studied for
many years. To better understand the causes and mecha-
nisms of these effects, it is important to continue this
research [2].
A variety of studies have shown the degree of neuro-
protective effect and how brain metabolism and neuro-
logical results are affected by volatile inhalation agents.
These data indicate that the neuroprotective effect
mechanisms of volatile agents may be related to factors
including activation of ATP-dependent potassium channels,
upregulation of nitric oxide synthase, reduction ofexcitotoxic stressors and cerebral metabolic rate,
augmentation of peri-ischemic cerebral blood flow, and
upregulation of antiapoptotic factors and mitogen-
activated protein kinases [25]. There are many studies
researching the neuroprotective/neurotoxic features of
intravenous agents. Propofol has a lower suppressive effect
on neuronal injury during ischemic depolarization
compared to thiopental [26]. Propofol causes oxygen
glucose destruction in the rat hippocampus that is linked to
concentration. Propofol provides neuroprotective effects
when present in the incubation medium during oxygen-
glucose deprivation and during the following 24-hour re-
covery period [2]. However, the role of propofol in trau-
matic brain damage is less well known, and there are
limited experimental studies on this topic [27]. In fact,
some animal studies have noted dose-linked neurodegen-
erative characteristics of propofol in the developing rat
brain [28].
Many in vivo and in vitro experimental ischemia models
have emphasized the protective effects and importance of
barbiturates against ischemic damage. While the first
studies of barbiturates proposed that the neuroprotective
effects were related to reducing metabolic requirements,
currently, it is known that all of the factors increasing
Figure 1. Effects of sugammadex treatment on neuronal density, crezyl-violet staining (A1e4), TUNEL (B1e4), and active
caspase-3 immunoreactivity (C1e4) in the CA1 region of the hippocampus. Neuronal density was significantly less in the IR group
(A2). TUNEL and active caspase-3-positive cells enhanced in the IR group (B2eC2). Sugammadex (100 mg/kg) treatment signifi-
cantly reduced the number of apoptotic neurons (B4eC4). Arrows indicate TUNEL-positive and active caspase-3 immune-positive
cells. IR Z ischemiaereperfusion; TUNEL Z terminal deoxynucleotidyl transferase dUTP nick end labeling.
Sugammadex and cerebral ischemia/reperfusion 297protein synthesis, GABA-nergic activity and antioxidant
activity play a role together [29]. Additionally, the
adenosine-induced excitator synaptic transfer inhibition
contributes to these mechanisms [30]. Although ketamine is
a well-known old agent and noncompetitive N-methyl-D-
aspartic acid (NMDA) receptor agonist with neuroprotective
effects, it did not provide neuroprotection in an experi-
mental spinal cord ischemia model [31]. In fact, the latest
experimental data indicate that neurodegenerative effects
are linked to dose and time exposure in developing animals
[32]. Frequently chosen for anesthetic administration dur-
ing surgery in recent years in addition to use in patients
under intensive care conditions, dexmedetomidine has
been shown to be neuroprotective in experimental studies
[33,34]. Dexmedetomidine preconditioning is known toprotect against cerebral I/R injury by hypoxia-inducible
factor-1a upregulation and vascular endothelial growth
factor expression [34]. Jeon et al. [1] studied the neuronal
effects of dexmedetomidine and sevoflurane used together
in a transient global cerebral ischemia model in rats and
found that preischemic dexmedetomidine and post-
conditioning sevoflurane administration did not provide
additional neuroprotective benefits.
While evidence-based knowledge of the neuronal effects
of anesthetic agents used from the past to the present is
available, the scientific data regarding new generation
agents is limited. Sugammadex is one of these. Sugamma-
dex has recently begun to be used in clinical neuromuscular
pharmacology and is a modified g-cyclodextrin molecule.
The unique molecular structure of sugammadex
Figure 2. Effects of sugammadex treatment on neuronal density, crezyl-violet staining (A1e4), TUNEL (B1e4) and active
caspase-3 immunoreactivity (C1e4) in the parietal cortex. The neuronal density is significantly less in the IR group (A2). TUNEL and
active caspase-3-positive cells enhanced in the IR group (B2eC2). Sugammadex (100 mg/kg) treatment significantly reduced the
number of apoptotic neurons (B4eC4). IRZ ischemiaereperfusion; TUNELZ terminal deoxynucleotidyl transferase dUTP nick end
labeling.
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removing it from the muscleenerve junction, and it is used
for the selective and rapid reversal of neuromuscular
blockage [11e13,35]. Cyclodextrins are frequently used in
the medicinal and food industries. Specifically, cyclodextrin
molecules are used to convert lipophilic agents to hydro-
philic forms. Some cyclodextrins can also alter the receptor
stability in membranes and the structure of the lipid stack,
affecting receptor functions and removing cholesterol from
the cell membrane. The three-dimensional structure of
sugar rings contained in cyclodextrins (D-glucopyranose
units) form a donut-like ring with an internal hollow trun-
cated cone or hydrophobic cavity and a hydrophilic outer
structure. They are named according to the number of
rings; a contains six, b contains seven and g contains eightsugar rings. There are narrow and wide openings caused by
primary and secondary faces. The negative hydroxyl groups
on the primary and secondary faces make the molecule
water soluble. The a1-4 bonds inside and their carbon
atoms provide the lipophilic cavity. Thus, the water-soluble
molecule surrounds a lipophilic core. This structure en-
capsulates lipophilic medications of appropriate size and
increases water solubility. Noncovalent thermodynamic in-
teractions form inclusion complexes (molecular encapsu-
lation). The size of the cavity is larger in g-cyclodextrins
than in a and b ones and is 0.8 nm. Thermodynamic, Van
der Waals, hydrophobic, hydrogen and load transfer in-
teractions contribute to the formation of inclusion com-
plexes (hosteguest complexes). The inclusion complex
encapsulates a lipophilic molecule [11e13,35].
Table 3 Effect of sugammadex treatment on neuronal density of the hippocampus (CA1, CA2, CA3 and GD regions) and pa-
rietal cortex of rats with IR brain injury.
Hippocampus
CA1 CA2 CA3 GD Parietal cortex
Group Sham (n Z 6) 52.06  2.05b,c 36.06  2.51d 29.30  3.16b,c,d 72.0  2.40b,c 34.45  2.10b,c,d
Group I/R (n Z 7) 33.01  3.49a,c,d 29.40  2.27a,c 19.46  1.56a,d 55.06  3.98a,b,d 25.06  1.04a,d
Group S 16 (n Z 7) 40.10  2.43a,b,d 34.15  2.47b 21.11  1.81a,d 62.05  1.95a,b,d 27.18  1.78a,d
Group S 100 (n Z 7) 50.75  1.72b,c 32.08  2.57a 24.20  1.98a,b,d 70.10  1.84b,c 31.04  1.34a,b,d
Data are presented as mean  standard deviation.
I/R Z ischemiaereperfusion.
a p < 0.05, compared with Sham group, ManneWhitney U test.
b p < 0.05, compared with I/R group, ManneWhitney U test.
c p < 0.05, compared with S 16 group, ManneWhitney U test.
d p < 0.05, compared with S 100 group, ManneWhitney U test.
Table 4 The Effect of sugammadex treatment on TUNEL- and caspase-3-positive cells of the hippocampus and parietal cortex
of rats with IR brain injury.
Hippocampus Parietal cortex
TUNEL-positive cells Caspase-3-positive cells TUNEL-positive cells Caspase-3-positive cells
Sham group (n Z 6) 1.91  0.11b,c,d 0.90  0.07b,c,d 4.60  0.32b,c,d 3.81  0.33b,c
I/R group (n Z 7) 10.50  0.69a,b,d 7.10  0.43a,d 11.13  0.47a,b,d 7.90  0.62a,b,d
S 16 group (n Z 7) 8.32  0.94a,b,d 6.85  0.39a,d 9.80  0.44a,b,d 6.24  0.39a,b,d
S 100 group (n Z 7) 4.70  0.61a,b,d 3.48  0.38a,b,d 5.91  0.53a,b,d 4.08  0.26b,d
Data are presented as mean  standard deviation.
I/R Z ischemiaereperfusion.
a p < 0.05, compared with Sham group, ManneWhitney U test.
b p < 0.05, compared with I/R group, ManneWhitney U test.
c p < 0.05, compared with S 16 group, ManneWhitney U test.
d p < 0.05, compared with S 100 group, ManneWhitney U test.
Table 5 Biochemical measurements.
TAS GPx SOD MDA
Sham group 1.93  0.34b 242.12  47.54b 0.58  0.29b 1.15  0.45b
I/R group IR 1.19  0.61a 165.71  57.87a 0.21  0.12a 2.51  1.53a
S 16 group 1.49  0.24 177.28  30.51 0.31  0.03 1.83  0.75
S 100 group 1.53  0.29 204.98  15.79 0.40  0.28 1.70  0.34
Data are presented as mean  standard deviation.
GPx Z glutathione peroxidase; MDA Z malondialdehyde; SOD Z superoxide dismutase; TAS Z total antioxidant status.
a p < 0.05, compared with Sham group, ManneWhitney U test.
b p < 0.05, compared with I/R group, ManneWhitney U test.
Sugammadex and cerebral ischemia/reperfusion 299Many cyclodextrin groups protect cortical neurons,
cultured without normal calcium signal effect, against
glutamate excitotoxicity and NMDA and oxygen-glucose
deprivation [36]. Methyl-b-cyclodextrin has been found to
protect the hippocampal areas from the effects of anoxia
[37]. Abulrob et al. [5] studied the cyclodextrin 2-
hydroxypropyl-b-cyclodextrin (HP-CD) and showed that it
had neuroprotective features. Yao et al. [38] conducted a
study in rats in which they administered HPCD and deter-
mined that cyclodextrins had clear neuroprotective effects
in their studies. In experimental studies, HP-CD is used as a
carrier for lipophilic medications and as an odor remover
[35]. Other lipophilic medication carriers such as ethanoland dimethylsulfide have neuroprotective characteristics
[36,37]. Frank et al. [6] reported that, as with other b-cy-
clodextrins, methyl-b-cyclodextrin reduced neuronal
excitability in the hippocampal area as methyl-b-cyclo-
dextrin treatment can separate cholesterol in the post-
synaptic area, causing disruption of NMDA and a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor-
linked glutamate transmission. There is a decrease in the
level of membrane cholesterol attenuated transporter-
mediated glutamate release from nerve terminals. There-
fore, lowering cholesterol may be used for neuroprotection
in stroke, ischemia, and traumatic brain injury, which are
associated with an increase in glutamate uptake reversal.
300 S. Ozbilgin et al.Rivers et al. [39] found that HP-CD administration 30
minutes after variable hypoxiaeischemia significantly
reduced brain injury in rats. The researchers found that the
protective effect of HP-CD continued effectively for at
least 15 days and was clearest in the striatum. They shared
the opinion that this may be key to motor functions in the
brain. They emphasized that this feature of cyclodextrins
provided hope for cerebral ischemia injury.
Due to the unique molecular structure and high molec-
ular weight (2178.01) of sugammadex, its transmission
across the BBB and the placenta is low [35]. This charac-
teristic appears to prevent any significant toxicity of
sugammadex derivatives in the central nervous system.
However, BBB permeability may change in different situa-
tions such as in the presence of neurodegenerative diseases
such as Alzheimer’s disease, Parkinson’s disease, traumatic
brain/spinal cord injury, ischemia, and infections or
immature nervous systems. Under these conditions,
sugammadex may pass the BBB in specific areas [7]. Palanca
et al. [7] showed that sugammadex causes apoptosis/ne-
crosis and neuron death in primary cell cultures linked to
concentration. In cell cultures, sugammadex increases the
expression of the monoclonal cytochrome C protein (CytC),
Apoptosis-inducing factor (AIF), anti-Smac/Diablo (1:500),
Sigma-Aldrich Biotech (Barcelona, Spain), and CASP-3 pro-
teins. They proposed that this role of sugammadex may be
related to changing cholesterol hemostasis with oxidative
stress and causing apoptotic activation. This is considered
to be due to differences in resistance/sensitivity to oxida-
tive stress between neuronal cell types [7].
The hypothesis of this study is that, similar to other
cyclodextrins, a g-cyclodextrin will reduce cerebral I/R
injury in a global cerebral hypoxia model in rats, and may
have neuroprotective characteristics. In our study, to test
this hypothesis, the role of sugammadex in transient global
cerebral I/R injury induced by bilateral common carotid
occlusion in rats was examined. In our study, compared
with the Sham group, histological scores and behavioral
neurological test results of cerebral and biochemical pa-
rameters in the I/R group showed that the experimental
cerebral I/R model was successfully induced. In the treat-
ment groups, in both the hippocampus and the parietal
cortex, immunohistochemical assessment showed that the
results of the TUNEL and caspase assays were lower than
those in the cerebral I/R group. These results appeared
better in the S 100 group. The high dose of sugammadex
was found to be more neuroprotective. This result is in
accordance with the total score obtained from behavioral
neurological evaluation tests in rats.
We did not evaluate antioxidant enzyme activity (TAS,
GPx, and SOD) and MDA content in tissues.
There is a need for pharmacological applications that
are cheap and simple, if possible, to reduce and/or prevent
the negative and unwanted results of hypoxia. These ap-
plications should reduce neurological damage and improve
patient prognosis. Sugammadex is frequently used in
routine anesthesia administration. Our hypothesis is that
sugammadex may have neuroprotective effects. The results
of this study found that sugammadex had a protective ef-
fect against I/R injury. Therefore, studies focusing on the
identification of potential therapeutic drugs for treatment
and on understanding the mechanisms of cerebralischemia/reperfusion injury are of great importance.
Repeating our study with different models and classes of
animals such as mice, rabbits, and swine will increase the
literature on this topic and will provide a greater under-
standing of the effect of sugammadex on neuronal injury.References
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